| Hao, Jihui |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
BESTPOP, NCT05594927: Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, ) |
|
|
| Recruiting | 3 | 261 | RoW | Icaritin, Huachansu | Beijing Shenogen Biomedical Co., Ltd | Hepatocellular Carcinoma | 08/25 | 08/25 | | |
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. |
|
|
| Recruiting | 3 | 220 | RoW | Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide. | Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 12/26 | 10/30 | | |
| Not yet recruiting | 2/3 | 146 | RoW | Nimotuzumab, h-R3, GX, Placebo | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 05/27 | 05/27 | | |
2023-012-00CH1, NCT06361888: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 482 | RoW | Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine | Hutchmed | Metastatic Pancreatic Cancer | 08/27 | 08/27 | | |
NCT04808687: Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 72 | RoW | Nab paclitaxel and S-1 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Neoplasms | 02/23 | 02/24 | | |
NCT06405685: Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, h-R3, AG | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 10/25 | 10/25 | | |
NCT04814485: Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer |
|
|
| Recruiting | 2 | 39 | RoW | SHR-1020+albumin-bound paclitaxel, Nab-paclitaxel， Paclitaxel-albumin | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 07/23 | 07/23 | | |
NCT06413017: Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, h-R3, ICIs(Immune checkpoint inhibitors), PD-1 or PD-L1 | Tianjin Medical University Cancer Institute and Hospital | HCC | 07/25 | 12/25 | | |
NCT05208177: A Study of SHR-1802 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 2 | 124 | RoW | SHR-1802＋camrelizumab + famitinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05947825: Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients |
|
|
| Not yet recruiting | 2 | 30 | NA | Combination of sitagliptin+ gemcitabine + nab-paclitaxel | Tianjin Medical University Cancer Institute and Hospital | PDAC - Pancreatic Ductal Adenocarcinoma | 08/24 | 08/24 | | |
NCT05908747: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer |
|
|
| Recruiting | 2 | 29 | RoW | surufatinib + gemcitabine + nab-paclitaxel | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 05/25 | 05/26 | | |
NCT05559541: Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 102 | RoW | AK119, AK104 | Akeso | Solid Tumor, Adult | 03/24 | 09/24 | | |
| Not yet recruiting | 1/2 | 96 | NA | Irinotecan liposome injection, Nal-IRI, Oxaliplatin, Eloxatin, 5-Fluorouracil, 5-FU, flurouracil, Adrucil, Leucovorin, Folinic Acid, SBRT | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 04/26 | 12/27 | | |
| Active, not recruiting | 1/2 | 220 | RoW | SHR-A1921； | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 02/26 | | |
NCT05868876: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 205 | RoW | AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion | Akeso | Advanced Malignant Tumors | 11/25 | 02/26 | | |
NCT04482257: Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. |
|
|
| Recruiting | 1 | 48 | RoW | Irinotecan Liposome Injection combined with 5-FU/LV | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Pancreatic Cancer | 12/20 | 03/21 | | |
NCT05173792: Study of AK119 in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 16 | RoW | AK119 | Akeso | Solid Tumor | 05/23 | 05/23 | | |
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1 | 67 | NA | HBM4003 and Triprilimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 05/24 | 05/24 | | |
NCT05125523: A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 264 | RoW | Sirolimus for Injection (Albumin Bound) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 06/24 | 11/24 | | |
| Recruiting | 1 | 65 | RoW | TQB3824 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 08/24 | 12/24 | | |
NCT05740202: A Trial of SHR-7367 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 182 | RoW | SHR-7367 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 11/25 | 11/25 | | |
| Recruiting | N/A | 10000 | RoW | | Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital | Gallbladder Neoplasms | 12/22 | 12/25 | | |
NCT05997147: A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | N/A | 1009 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Predictive Cancer Model, Pancreas Cancer | 08/23 | 08/23 | | |
NCT06208436: The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer |
|
|
| Recruiting | N/A | 250 | RoW | Adjuvant chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Pancreas Cancer, Chemotherapy | 02/24 | 02/24 | | |
NCT06717022: A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors |
|
|
| Recruiting | N/A | 24 | RoW | CHT102 allogeneic CAR T cells | Tianjin Medical University Cancer Institute and Hospital, Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. | Mesothelin Positive Tumors | 06/26 | 05/39 | | |
| Li, Lanfang |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
|
|
| Recruiting | 1/2 | 112 | RoW | Prizloncabtagene autoleucel, C-CAR039 | Shanghai AbelZeta Ltd. | Relapsed/Refractory Large B-Cell Lymphoma | 10/25 | 12/27 | | |
NCT04250324: Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma |
|
|
| Recruiting | 1 | 21 | RoW | BZ019 | Shanghai Cell Therapy Group Co.,Ltd, Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital | Large B-cell Lymphoma | 08/22 | 12/22 | | |
NCT04696432: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 1 | 7 | RoW | Prizloncabtagene autoleucel, C-CAR039 | Tianjin Medical University Cancer Institute and Hospital, Cellular Biomedicine Group Ltd. | Non-Hodgkin's B-cell Lymphoma | 07/23 | 12/23 | | |
NCT06318884: A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 1 | 76 | RoW | SCTB35 injection, none other names | Sinocelltech Ltd. | Non-Hodgkin Lymphoma, B-cell | 10/26 | 12/27 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
